The galacotsylated albumin nanoparticles were prepared for the selective delivery of Cimetidine to the asialoglycoprotein receptor (ASGP-R) which is particularly presents on mammalian hepatocytes. The albumin nanoparticles (NPs) were prepared by using desolvation method and efficiently conjugated with galactose. Various parameters such as particle size, % entrapment efficiency and drug loading efficiency, percentage yield, in vitro drug release, were determined. The size of nanoparticles (both plain and galactose coated) was found to be in range of 200-250 nm, and maximum drug payload was found to be 19.08% ± 1.10 .The maximum drug content was found to be 30.80% ± 0.3 and 27.09% ± 0.5 respectively in plain and galactose coated nanoparticles while the maximum entrapment efficiency was found to be 90.68% ± 0.5 and 91.75% ± 0.59 in plain and coated nanoparticles. It was also found that coating of nanoparticles increases the size of nanoparticles. From the in-vitro studies, it was concluded that increase in polymer concentration, decreases the drug releases from the nanoparticles.
Introduction
Hepatotoxicity is a direct liver injury caused by the toxic metabolite of acetaminophen. When taken in therapeutic doses, greater than 90% of acetaminophen is metabolized to phenolic glucuronide and sulfate in the liver by glucuronyltransferases and sulfotransferases and subsequently excreted in the urine. Of the remaining acetaminophen, about 2% is excreted in the urine unchanged. Approximately 5% to 10% is metabolized by cytochrome P450, mainly the enzyme CYP2E1, to N-acetyl-p-benzoquinoneimine (NAPQI), a highly reactive, electrophilic molecule that causes harm by formation of covalent bonds with other intracellular proteins. This reaction is prevented by conjugation with glutathione and subsequent reactions to generate a water-soluble product that is excreted into bile. With acetaminophen overdose, glucuronyltransferases and sulfotransferases are saturated, diverting the drug to be metabolized by cytochrome P450 and generating NAPQI in amounts that can deplete glutathione.
Targeted delivery of drugs and proteins to liver can be achieved via asialoglycoprotein receptor, which can recognize and combine the galactose-and N-acetygalatosamine terminated glycoproteins. Glycosyl is usually conjugated with drugs directly to fabricate prodrugs or with nanoparticles encapsulated drugs via forming covalent bonds, while the covalent bonds may lead to some shortages for drug release. Therefore, we can prepare nanoparticles for efficient targeting by glycosylation using galactosylated polymer as a carrier to entrap the model drugs in nanoparticles core physically rather than forming covalent drug conjugation. The means of incorporation of drug in nanoparticles may improve drug release to maintain its activity, raise its therapeutic index and diminish the adverse effect. Due to their nanometer-size and galactosyl, the nanoparticles may be a potential delivery system for passive and active targeting to liver parenchymal cells for therapy of hepatitis and liver injury. [5] The asialoglycoprotein receptor (ASGP-R) which is particularly presents on mammalian hepatocytes can be utilize for active targeting by using its natural and synthetic ligands. By utilizing this receptors can provides a unique means for the development of liver-specific carriers, such as liposomes, recombinant lipoproteins, and polymers for drug or gene delivery to the liver, especially to hepatocytes. These receptors recognize the ligands with terminal galactose or Nacetylgalactosamine residues, and endocytose the ligands for an intracellular degradation process . [5] Nanoparticles can be defined as the colloidal particles having size ranging from 10 to 1000 nm. The advantages of nanotechnology is to provide the safe and the effective medicine (nanomedicine). A large number of drugs can be delivered using a nanoparticulate carriers via a large number of routes. These includes many hydrophilic drugs, hydrophobic drugs as well as for proteins, vaccines, biological macromolecules, etc. They can be formulated for targeted delivery to the lymphatic system, brain, arterial walls, lungs, liver, spleen, or made for long-term systemic circulation
. [6] The major goals in designing nanoparticles as a delivery system are to control particle size, surface properties and release of pharmacologically active agents in order to achieve the site-specific action of the drug at the therapeutically optimal rate and dose regimen.
Albumin is an attractive macromolecular carrier and widely used to prepare nanospheres and nanocapsules, due to its availability in pure form and its biodegradability, nontoxicity and nonimmmunogenicity. Both Bovine Serum Albumin or BSA and Human Serum Albumin or HSA have been used. As a major plasma protein, albumin has a distinct edge over other materials for nanoparticle preparation. On the other hand, albumin nanoparticles are biodegradable, easy to prepare in defined sizes, and carry reactive groups (thiol, amino, and carboxylic groups) on their surfaces that can be used for ligand binding and/or other surface modifications and also albumin nanoparticles offer the advantage that ligands can easily be attached by covalent linkage. Drugs entrapped in albumin nanoparticles can be digested by proteases and drug loading can be quantified. A number of studies have shown that albumin accumulates in solid tumors making it a potential macromolecular carrier for the site-directed delivery of antitumor drugs. [7, 8, 9] galactosylated nanoparticulated delivery of Cimetidine the reqiured action of drug at the target site i.e at liver can be provided. The advantage of targeting helps to reduce the systemic side effects which may be occur due to the distribution of the drug to the other organs and thus helps in maintain the required concentration of drug at the desired site. Moreover, as nanoparticles have high carrier capacity (i.e drug molecules can be incorporated in the polymer matrix), helps to provides the sustain action and thus reduces the dose frequency and increases the patient compliance. In the current work, we had prepared galactosylated albumin nanoparticles using desolvation method. The coating of nanoparticles with galactose helps to gets binds the nanocarriers with the asialoglycoprotein receptor presents in hepatocytes and improves the immunotherapeutic effects. The developed formulations overcome the drawbacks and limitations of the conventional drug delivery systems.
Materials and methods

Materials
Cimetidine was a gift sample from Windlas Biotech Ltd, Dehradun, sterile bovine serum albumin, sodium chloride, ethanol were purchased from Central Drug House Ltd, New Delhi. All the reagents and solvents used were of analytical grade satisfying Pharmacoepial standards.
Preformulation Studies
Preformulation testing is the first step in the rational development of dosage forms of a drug. It can be defined as the investigation of physical and chemical properties if drug substance alone or in combination with excipients. The overall objective of preformulation studies is to generate information useful to formulator in developing stable and bioavailable dosage forms which can be mass produced.
Identification tests
Identification of drug by FTIR
Infrared spectrum of Cimetidine was determined by using Fourier Transform Infrared Spectrophotometer using KBr disks method. The sample (0.5 to 1.0 mg) is finely grounded and intimately mixed with approximately 100 mg of dry potassium bromide powder. Grinding and mixing can be done with mortar and pestle. The mixture is then pressed into a transparent disk in an evacuable die at sufficiently high pressure. Suitable KBr disks or pellets can often be made using a simpler device such as a hydraulic press. The base line correction was done using dried potassium bromide. Then ,the spectrum of dried mixture of drug and potassium bromide was scanned from 4000 cm -1 to 400 cm -1 .
[10]
Organoleptic characteristics
The colour, odour and taste of the drug were characterized and recorded.
Solubility
The solubility of the drug were checked in different solvents like distilled water, buffers, ethanol and organic solvents and recorded. This might be helpful in selection of a suitable solvent to dissolve drug as well as excipients used in formulations.
Melting Point determination:
The sample was loaded into a sealed capillary (melting point capillary) which was then placed in the melting point apparatus. The sample is then heated & as the temperature increases the sample was observed to detect the phase change from solid to liquid phase. The temperature at which this phase change occurs gives the melting point.
Particle size analysis
Determination of Particle Size by optical microscopy
The size of drug particle was determined with the help of optical microscopy. Firstly, the least count of microscope was determined by adjusting stage and ocular micrometer. Then, a drop of drug suspension was placed in a slide and spread into a thin film with coverslip and observed under microscope at 45X with ocular to count the particle size. A total of 100 particles were counted and their size was determined. The average particle size in micrometers was determined and recorded.
Spectral Studies
Drug -excipient Compatibility Study
Drug and polymer was mixed in the equal ratio and finally grounded and intimately mixed with approximately 100 mg of dry potassium bromide powder. Grinding and mixing was done with mortar and pestle. The mixture is then pressed into a transparent disk in an evacuable die at sufficiently high pressure. Suitable KBr disks or pellets have been prepared using a simpler device such as a hydraulic press. The base line correction was done using dried potassium bromide. Then, the spectrum of dried mixture of drug and potassium bromide was scanned from 4000 cm -1 to 400 cm -1 .
Preparation of Calibration Curve of Cimetidine a. Preparation Of Phosphate Buffer pH 7.4
Accurately weighed 6.804gm of potassium dihydrogen phosphate was dissolved in 250ml of distilled water; 2.00 gm of sodium hydroxide was dissolved separately in 250 ml of distilled water. Then, 62.5 ml of potassium dihydrogen phosphate was taken in a separate 200 ml volumetric flask, added 48.87 ml of sodium hydroxide and then add water to volume. The pH was determined by pH meter.
b. Determination of λmax of Cimetidine
Phosphate Buffer pH 7.4 was investigated to develop a suitable UV-spectrophotometric method for the analysis of Cimetidine in formulations. For selection of media the criteria employed were sensitivity, ease of sample preparations, solubility of drug, cost of solvents and applicability of method to various purposes. An UV spectroscopic scanning run (200-400 nm) was carried out to select the best UV wavelength for detection of Cimetidine in buffer. The analysis was carried out using phosphate buffer pH 7.4 as blank. Absorbance of Cimetidine was determined.
c. Calibration Curve of Cimetidine
A stock solution of 100 mcg/ml of Cimetidine was prepared in phosphate buffer pH 7.4 by dissolving 10 mg of drug in 100ml of the media. For preparations of different concentrations, aliquots of stock solution were transferred into a series of 10 ml standard flasks and volumes were made with respective media. The different concentrations were prepared in the range of 0.2-4 mcg/ml of Cimetidine in phosphate buffer pH 7.4 for standard curve. 
Formulation of Nanoparticles
Preparation of Master Formula
Preparation of Bovine Serum Albumin nanoparticles from desolvation method
Bovine Serum Albumin nanoparticles were prepared by a desolvation technique .The different amounts of bovine serum albumin (i.e 50, 150, 250, 350 mg) was dissolved in 2.0 ml of 10mM NaCl solution, respectively, titrated to pH 8. The specified amount of drug was then added into bovine serum albumin solutions followed by the continuous addition of 8.0 ml of the desolvating agent i.e. acetone under stirring (500 rpm) at room temperature. After the desolvation process, 8% glutaraldehyde in water was added to induce particle crosslinking. The crosslinking process was performed under stirring of the suspension over a time period of 24 h.
Purification of Bovine Serum Albumin nanoparticles
The resulting nanoparticles were purified by three cycles of differential centrifugation (10,000 rpm for 10 min) and redispersion of the pellet to the original volume 10mM NaCl at pH values of 8, respectively. Each redispersion step was performed in an ultrasonication bath over 5 min. The solvent was removed and the nanoparticles were collected and stored in a refrigerator.
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Galactose coating of Nanoparticles
20 mg of galactose were added to 10 mg of bovine serum albumin loaded nanoparticles which is dispersed in 5 mL acidic phosphate buffer saline (pH 5.0), and the mixture was then stirred at room temperature over-night. The resulting nanoparticles were purified by three cycles of differential centrifugation (10,000 rpm for 10 min) and followed by redispersion of the pellet to the original volume in 10mM NaCl at pH 8, respectively. Each redispersion step was performed in an ultrasonication bath over 5 min. The solvent was evaporated and the nanoparticles were collected and stored at 2-8 ο C.
Fig.1.1: Schematic Representation of Desolvation Method
Characterization of Nanoparticles
The formulated nanoparticles were evaluated for particle size, shape, zeta potential, drug content uniformity, entrapment efficacy, drug loading and in-vitro drug release study.
Shape and Size
The morphology and size of plain and galactose-coated nanoparticles was determined by Scanning electron microscopy (SEM).( Zeiss, Evo 40, India).
Drug content uniformity
500 mg of nanoparticles were weighed and crushed in mortar and pestle. A powder equivalent to 10 mg was taken and introduced in a 100ml volumetric flask. The nanoparticles were dissolved in phosphate buffer pH 7.4 and make up the volume upto 100ml. The above solution was analyzed by UV spectrometer at 234 nm.
Entrapment efficiency and Loading efficiency
The entrapment efficiency and drug loading of the prepared nanoparticles was calculated by the formula:
‫݃ݑݎܦ‬ ‫݈݃݊݅݀ܽ‬ ‫ݕ݂݂ܿ݊݁݅ܿ݅݁‬ ሺ%ሻ = ‫ݐ݊ݑ݉ܣ‬ ‫݂‬ ‫݃ݑݎ݀‬ ݅݊ ‫ݏ݈݁ܿ݅ݐݎܽ݊ܽ݊‬ ‫ݐ݊ݑ݉ܣ‬ ‫݂‬ ‫݃ݑݎ݀‬ ‫݈݀݁݀ܽ‬ ‫ݏ݈݁ܿ݅ݐݎܽ݊ܽ݊‬ × 100
Percentage Yield
It is calculated to know about the efficiency of any method, thus it helps in selection of appropriate method of production. Practical yield was calculated as the weight of nanoparticles recovered from each batch in relation to the sum of starting material. It can be calculated using following formula:
In vitro drug release:
In vitro drug release study was carried out by Modified Diffusion Apparatus. The apparatus consists of a beaker containing 50 ml of phosphate buffer pH 7.4 maintained at 37 ᵒ C under mild agitation (50 rpm) using a magnetic stirrer acts as receptor compartment.
An open ended tube acts as donor compartment and the egg membrane was tied into upper part of the donor compartment. The nanoparticles (plain and galactose coated) equivalent to 10 mg were placed into the donor compartment over the membrane which was dipped in the receptor compartment consisting buffer. Then, the samples were taken at different time intervals from the receptor compartment and was analyzed by UV spectrometer at 234 nm.
Mathematical modeling:
The data obtained from in vitro release studies was treated by various conventional mathematical models (zero-order, first-order, Higuchi, Korsmeyer-Peppas) to determine the release mechanism from the designed nanoparticle formulations. [11] [12] [13] Selection of a suitable release model was based on the values of R (correlation coefficient), k (release constant) and n (diffusion exponent) obtained from the curve fitting of release data. Page 209
Results and discussions
Four formulations of Cimetidine were formulated using different drug polymer ratios. The formulation is subjected to evaluation parameters like particle size, zeta potential, drug content uniformity, percentage yield, entrapment efficiency, drug loading efficiency, in-vitro drug release study. The comparison between the peaks of two graphs shows that the characteristics peaks of Cimetidine (taken from I.P.) was found similar to the given drug sample, which shows that the drug is Cimetidine.
Preformulation
Organoleptic characteristics
The colour, odour and taste of the drug were characterized and recorded using descriptive terminology, the results are shown in Mineral acids Very Soluble 1
Melting Point determination
The melting point of Cimetidine was found to be 140-145 ο C. This value is same as that of the literature citation of 139-144 ο C. The average particle size of the Cimetidine was found to be 1. Page 213
The drug-polymer interactions shows that there was no major shifts in the absorption bands(peaks) of Cimetidine in presence of polymer and it was observed that all the characteristics peaks of drug is present in the combination of drug and polymer spectra indicating the compatibility of drug with the polymer used.
Preparation of Calibration Curve of Cimetidine
Determination of λmax of Cimetidine UV absorption spectrum showed λ max to be 234nm.The graph of absorbance Vs concentration for Cimetidine was found to be linear in the concentration range of 0.2-4 mcg/ml at 234 nm. Hence, the drug obeys Lambert-beer's law in this range. Fig.2 .5 shows UV spectrum of Cimetidine and Fig. 2.6 . Shows the calibration curve of Cimetidine in phosphate buffer pH 7.4. The calibration curve was prepared and results was shown in Table 6 .8.
Fig 2.5.: UV Spectrum of Cimetidine
Wavelength of maximum absorption (λ max) in Phosphte buffer pH 7.4 was found to be 234nm. 
11.
4.0 0.8749
12.
4.4 0.9523 
Characterization of Nanoparticles 3.3.1. Particle Size
The particle size of all batches of plain nanoparticles was found to be in the size of 200 nm and that of galactose coated nanoparticles was found to be in the size range of 250 nm.
The SEM photomicrographs of nanoparticles are shown in Fig.2.7 (A & B) . It was observed from these photomicrographs that all samples of particles were smooth, sub-spherical in shape and aggregated to form small clusters.
The larger particle size of galactosylated nanoparticles as compared to plain nanoparticles could be due to the anchoring of galactose molecule at the surface of nanoparticles and hence an increment in size of nanoparticles was observed. 
Drug content uniformity
The drug content of different formulations F1 to F4 was calculated and the content was found to be in range of 20.09 to 30.80 % to plain nanoparticles and 19.51 to 27.09 % for coated nanoparticles. The maximum drug content was found to be 30.80% for plain nanoparticles and 27.09% for coated nanoparticles in formulation F3. The results is shown in Table 2 .9. Comparison of drug content for formulations F1 to F4 is shown in Fig.2.8 The reason of low drug content was due to drug partitioning to the external aqueous phase during formulation, which also leads to the low drug loading efficiency. 
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Entrapment efficiency and Drug loading efficiency:
The entrapment efficiencies of all four formulations were given in the Fig. 2.9 .The maximum entrapment efficiency was found to be 90.68% and 91.75 % for the formulation F3. The entrapment efficiencies of nanoparticles are larger than 80%, the drug can be effectively loaded inside the nanoparticles. The entrapment efficiency increases with increasing polymer concentration upto a certain ratio.
The relatively higher percent drug entrapment was obtained for coated nanoparticles as compared to the plain nanoparticles which could be due to minimum repulsion between drug and polymer. Fig.2.10 . . Loading efficiency may be increased by increasing the polymer ratio, so that sufficient quantity of polymer will be able to entrap the drug present in solution.
The main reason for low drug loading efficiency was low drug-polymer binding. The drug has low protein binding therefore, most of the drug can easily diffuses through the matrix. Further, the existing albumin-based drug delivery systems are often limited by their low drug loading capacity as well as noticeable drug leakage into the blood circulation. 
Percentage Yield
The percentage yield of different formulations F1 to F4 were calculated and the yield was found to be in the range of 32.14 to 70.24% for plain nanoparticles and 25.98 to 62.32% for coated nanoparticles. Percentage yield of all batches is shown in Table 2 .12.Comparion of percentage yield for formulations F1 to F4 is shown in Fig.2.11 .The maximum percentage yield was found to be 70.24% and 62.32% for plain and coated nanoparticles in formulation F4, where the Page 219 concentration of albumin is highest while the nanoparticle yield is lowest in F1 i.e. 32.14% and 25.98 % where the concentration of albumin is lowest.
The reduction in percentage yield after coating of nanoparticles might be occur due to the loss of nanoparticles during the coating process. 
In vitro drug release
The dissolution study on all four formulations of Cimetidine were carried out in phosphate buffer pH 7.4 using egg membrane and modified apparatus. The in-vitro drug release of all four formulations F1 to F4 are shown in Table 2 .13.The cumulative percent drug release after 10 hrs was found to be between 35.01 % to 51.78% for formulations F1 to F4 respectively. From the results, it was concluded that increase in polymer concentration, decreases the drug releases from the nanoparticles.
It was also found that coating of nanoparticles with galactose retard the rate of drug release as compared to plain nanoparticles. The data obtained from in-vitro release studies was treated by various conventional mathematical models (zero-order, first-order, Higuchi and Korsmeyer-Peppa's) to determine the release mechanism from the designed nanoparticle formulations. Selection of a suitable release model was based on the values of R (correlation coefficient), k (release constant) and n (diffusion exponent) obtained from the curve fitting of release data. Page 228
The regression coefficients of the all formulations F1 to F4 are shown in Table 2 .18.
It was found that all the formulations follows the first order kinetics.The regression coefficients for the formulations F1 to F4 of Higuchi plot was found to be almost linear. The linearity suggests that the release of Cimetidine nanoparticles was diffusion controlled.
Korsmeyer-Peppas release model is widely used when the release mechanism is not well known or when more than one type of release phenomenon could be involved. The value of n could be used to characterize different release mechanism. The value of n for F1 to F4 was found to be respectively greater than 0.8. The formulations F1 and F2 indicates that the release approximates non-Fickian diffusion mechanism while the formulations F3 and F4 shows the Super Case-II tramsport mechanism. 
Conclusion
In the present study , an attempt was made to develop galactosylated albumin nanoparticles of Cimetidine for treatment of Acetaminophen induced hepatotoxicity with a view to provide targeted action to the required site and helps to provides the sustain action and thus reduces the dose frequency and increases the patient compliance.
From the results, it can be concluded that:
• Nanoparticles were successfully prepared by desolvation method. The method was able to produce discrete, free-flowing nanoparticles.
• FTIR studies were carried out to find out the possible interaction between the drug and the polymer. The study revealed that there was no interaction between the selected drug and polymer.
